Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
Predicting Patient Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: A Comparison of Measurable Residual Disease (MRD) Assessment by Digital Polymerase Chain Reaction and Conventional MRD
Peking University People's Hospital
300 participants
Jan 8, 2024
OBSERVATIONAL
Conditions
Summary
A research investigation into the efficacy of digital Polymerase Chain Reaction (dPCR) for monitoring measurable residual disease (MRD) during allogeneic hematopoietic stem cell transplantation, with a focus on predicting relapse in patients diagnosed with leukemia, myelodysplastic syndromes (MDS), and related hematological conditions.
Eligibility
Inclusion Criteria3
- The presence of at least one fusion gene or hematological tumor-associated mutation detected at diagnosis by NGS or real-time PCR provided for posttransplant MRD monitoring.
- Neutrophil engraftment
- Received at least one MRD monitoring by digital PCR after HSCT
Exclusion Criteria2
- Patients who relapsed or died before the first digital PCR monitoring
- Patients only with mutations in DNMT3A, TET2, and ASXL1 ("DTA mutations") or only germline mutations
Interventions
digital Polymerase Chain Reaction (dPCR)
Real-time Polymerase Chain Reaction (real-time PCR)
Multicolor Flow Cytometry
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06211166